May 9 |
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
|
Apr 18 |
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
|
Mar 20 |
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
|
Mar 10 |
Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
Mar 8 |
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Lumos Pharma GAAP EPS of -$4.18 misses by $0.13, revenue of $2.05M beats by $0.83M
|
Mar 7 |
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Mar 6 |
Lumos Pharma FY 2023 Earnings Preview
|